Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6143290
Tumor regression by adenovirus expression of wild-type p53
expired -
US 6143558
Optical fiberless sensors for analyzing cellular analytes
expired -
US 6143719
Bradykinin analogs as selective thrombin inhibitors
expired -
US 6140083
Leptospiral outer membrane protein, LipL46
expired -
US 6140068
Protease resistant compositions for wound healing
expired -
US 6140364
Arachidonic acid metabolite, 16-HETE
expired -
US 6136532
Methods for treating bipolar mood disorder associated with markers on chromosome 18q
expired -
US 6136306
Method for treating tumors
expired -
US 6136539
Compositions and methods for the inhibition of MUC-5 mucin gene expression
expired -
US 6132962
Retroviral vectors comprising an anti-hiv or other nucleic acid
expired -
US 6133232
Endoderm, cardiac and neural inducing factors
expired -
US 6132987
Recombinant mammalian monocyte chemotactic protein-1 (MCP-1) receptors (MCP-1R, CCR-2)
expired -
US 6133320
Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
expired -
US 6133324
Use of perillyl alcohol in organ transplantation
expired -
US 6133424
ppRB.sup.110 - nuclear phosphoprotein-the retinoblastoma susceptibility gene product
expired -
US 6132729
Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
expired -
US 6132730
Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment
expired -
US 6132724
Allelic polygene diagnosis of reward deficiency syndrome and treatment
expired -
US 6130254
Methods for inhibiting photoaging of skin
expired -
US 6126946
Hepatocyte-selective oil-in-water emulsion
expired -
US 6127178
Apoptotic peptides
expired -
US 6127598
NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity
expired -
US 6127520
Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
expired -
US 6123941
Method for restoration of normal phenotype in cancer cells
expired -
US 6124278
Acylbenzoxazines for enhancing synaptic response
expired -
US 6124271
Method and conjugate for treating H. pylori infection
expired -
US 6124101
Recombinant thrombin receptor and related pharmaceuticals
expired -
US 6123938
Human urinary hyaluronidase
expired -
US 6124262
Compositions and methods for reducing adhesiveness of defective red blood cells
expired -
US 6123918
Hyperolius argus endocrine screen test
expired -
US 6120777
High fluorescence specific immune enhancing factor and methods of use for same
expired -
US 6120799
Cationic lipid compositions targeting angiogenic endothelial cells
expired -
US 6121469
Therapeutically effective 1.alpha.,25-dihydroxyvitamin D.sub.3 analogs
expired -
US 6117858
Compositions and methods for altering the biodistribution of biological agents
expired -
US 6117975
Melanocortin receptor polypeptides MC-3, MC-4, and MC-5
expired -
US 6117839
Bone stimulating factor
expired -
US 6113946
Self-assembling polynucleotide delivery system comprising dendrimer polycations
expired -
US 6114545
Inhibitors of cholesterol esterase
expired -
US 6113951
Use of thiol redox proteins for reducing protein intramolecular disulfide bonds, for improving the quality of cereal products, dough and baked goods and for inactivating snake, bee and scorpion toxins
expired -
US 6113905
Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
expired -
US 6114504
Use of thiol redox proteins for reducing protein intramolecular disulfide bonds, for improving the quality of cereal products, dough and baked goods and for inactivating snake, bee and scorpion toxins
expired -
US 6114110
Isolation and propagation of a human herpesvirus derived from AIDS-associated Kaposi's sarcoma cells
expired -
US 6110743
Development and use of human pancreatic cell lines
expired -
US 6110740
Human vault RNA
expired -
US 6110695
Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
expired -
US 6110463
Anti-Cryptosporidium parvum preparations
expired -
US 6110448
Method for causing skin lightening
expired -
US 6110468
Vaccine for swine infertility and respiratory syndrome and method of use thereof
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory